Database Lock Completed for Innovation Pharmaceuticals' Phase 2 Clinical Trial of Brilacidin for COVID-19

Rhea-AI Summary

Innovation Pharmaceuticals (OTCQB:IPIX) announced the completion of the database lock for its Phase 2 clinical trial of Brilacidin aimed at treating moderate-to-severe COVID-19 in hospitalized patients. Statistical analysis is currently in progress, with topline results expected to be released during the week of November 8, 2021.

This milestone is crucial as it marks a significant step forward in the clinical evaluation of Brilacidin, which may provide new therapeutic options for COVID-19 patients.

Positive

• Database lock completed for Phase 2 trial of Brilacidin.
• Topline results expected by November 8, 2021.

Negative

• None.

WAKEFIELD, MA / ACCESSWIRE / November 3, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical-stage biopharmaceutical company, today announced that the Company has received confirmation that hard lock of the database was completed for its Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897). Statistical analysis is underway, with topline results for the trial anticipated to be reported during the week of November 8, 2021.

Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/

About Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical-stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious diseases, and dermatologic diseases.

Forward-Looking Statements: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements concerning future drug development plans, statements regarding the antiviral capabilities and therapeutic potential of Brilacidin and its impact on SARS-CoV-2 (COVID-19) and other viruses, as well as obtaining government regulatory approvals to commence clinical testing. Other statements regarding future product developments, and markets, including with respect to specific indications, and any other statements which are other than statements of historical fact. These statements involve risks but not limited to risks related to conducting pre-clinical studies and clinical trials and seeking regulatory and licensing approvals for Brilacidin and Kevetrin in the US and other jurisdictions; that prior test results may not be replicated in future studies and trials, uncertainties and assumptions that could cause the Company's actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are the Company's need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock under securities purchase agreements; the fact that the Company's licensee(s) may not successfully complete pre-clinical or clinical testing and the Company will not receive milestone payments, or the fact that the Company's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in the Company's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. The Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

INVESTOR AND MEDIA CONTACTS
Innovation Pharmaceuticals Inc.
Leo Ehrlich
info@ipharminc.com

SOURCE: Innovation Pharmaceuticals Inc.

View source version on accesswire.com:
https://www.accesswire.com/670897/Database-Lock-Completed-for-Innovation-Pharmaceuticals-Phase-2-Clinical-Trial-of-Brilacidin-for-COVID-19

FAQ

What is the significance of the database lock completion for IPIX?

The completion of the database lock indicates that data collection for the Phase 2 trial of Brilacidin has been finalized, allowing for statistical analysis to commence, which is vital for evaluating the drug's effectiveness.

When will the results of the Phase 2 trial of Brilacidin be available?

Topline results are anticipated to be reported during the week of November 8, 2021.

What is the purpose of the Phase 2 clinical trial for Brilacidin?

The trial aims to assess the efficacy of Brilacidin in treating moderate-to-severe COVID-19 in hospitalized patients.

How might the trial results impact Innovation Pharmaceuticals (IPIX)?

Successful trial results could enhance IPIX's market position and attract potential investors, while negative results may hinder the drug’s development and impact stock performance.